- The fund’s investments to date include ArsenalBio, Metsera, Mirador Therapeutics and Xaira Therapeutics
- Fund XIII follows the nearly $3bn Fund XII announced in June 2022
- ARCH Venture Partners invests in life science and tech companies
ARCH Venture Partners has closed on more than $3 billion for ARCH Venture Fund XIII, which will back early-stage biotechnology companies.
Fundraising took about nine months, according to fundraising data from affiliate title Buyouts. Investors include Alaska Permanent Fund, which committed $50 million, or twice the amount it invested in Fund XII, and Rockefeller Brothers Fund, which committed $10 million, Buyouts reported.
The new fund will invest in early-stage companies that prevent, detect and cure disease. It has already made investments in ArsenalBio, Metsera, Mirador Therapeutics and Xaira Therapeutics.
“We believe AI and new data-driven insights into biology will help to enable a more preventive, curative and equitable healthcare system,” ARCH co-founder and managing director Robert Nelsen said in a statement. “ARCH intends to continue driving the healthcare revolution.”
Fund XIII follows the $2.975 billion Fund XII announced in June 2022.
ARCH is based in Chicago and has offices in Seattle and San Francisco.
- The fund’s investments to date include ArsenalBio, Metsera, Mirador Therapeutics and Xaira Therapeutics
- Fund XIII follows the nearly $3bn Fund XII announced in June 2022
- ARCH Venture Partners invests in life science and tech companies
ARCH Venture Partners has closed on more than $3 billion for ARCH Venture Fund XIII, which will back early-stage biotechnology companies.
Fundraising took about nine months, according to fundraising data from affiliate title Buyouts. Investors include Alaska Permanent Fund, which committed $50 million, or twice the amount it invested in Fund XII, and Rockefeller Brothers Fund, which committed $10 million, Buyouts reported.
The new fund will invest in early-stage companies that prevent, detect and cure disease. It has already made investments in ArsenalBio, Metsera, Mirador Therapeutics and Xaira Therapeutics.
“We believe AI and new data-driven insights into biology will help to enable a more preventive, curative and equitable healthcare system,” ARCH co-founder and managing director Robert Nelsen said in a statement. “ARCH intends to continue driving the healthcare revolution.”
Fund XIII follows the $2.975 billion Fund XII announced in June 2022.
ARCH is based in Chicago and has offices in Seattle and San Francisco.
